分子影像引导下针对前列腺癌挽救性立体定向放射治疗:对复发灶区进行放射剂量递增,对未受累区进行剂量递减,以降低治疗毒性 (MIDAS-SBRT)
在前列腺癌抢救性放疗中使用立体定向放射治疗(SBRT),通过分子影像学指导,对复发病灶进行放射剂量递增,对未受累区域进行剂量递减,以降低治疗毒性
This is a single arm trial that is recruiting a total of 50 participants that have been diagnosed with prostate bed (where the prostate was taken out) or regional (surrounding lymph nodes) recurrence of a prostate cancer following surgery. Salvage radiation treatment represents the main treatment option, with long-term cure rates on the order of 70%. Currently, salvage radiation treatment to the prostate bed and the pelvic lymph nodes is delivered using external beam radiation therapy (EBRT) in 20-33 sessions, over 4-6.5 weeks. Potential study participants have undergone a PSMA PET scan, which has found recurrent cancer in the prostate bed or lymph nodes. This study will investigate personalizing your radiation treatment based on this information. Participants on this study will receive lower than standard radiation dose to areas of the surgical site which do not show evidence of disease on the scan.
This personalized radiotherapy will be delivered in 5 treatments over two weeks, rather than the four to 6 weeks which is the current standard of care. Participants will have a routine history, blood collection for PSA and hormone levels, toxicity assessment, and EPIC-26 & IPSS questionnaires at each follow-up visit. These will take place at 1, 3, 6, 12, 24, 36, and 60 months after radiation treatment.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段2
联系人和位置
学习联系方式
- 姓名:Andrew McPartlin, MD
- 电话号码:4855 416-946-4501
- 邮箱:andrew.mcpartlin@uhn.ca
学习地点
-
-
Ontario
-
Toronto、Ontario、加拿大、M5G 2M9
- University Health Network - Princess Margaret Cancer Center
-
接触:
- Andrew McPartlin, MD
- 电话号码:4855 416-946-4501
- 邮箱:andrew.mcpartlin@uhn.ca
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age ≥ 18 years old.
- Histologically proven initial diagnosis of adenocarcinoma prostate cancer.
- Radical prostatectomy > 6 months prior to commencing SBRT.
- Biochemical relapse with local and/or regional recurrence proven with PSMA PET
- ECOG 0-1.
Exclusion Criteria:
- Presence of para-aortic lymph nodes or distant metastasis.
- Chronic pelvic inflammatory disease.
- Contraindication for radiation treatment.
- Previous radiation treatment within the pelvis.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Molecular Imaging Informed Radiation Dose Escalation and De-escalation
Molecular imaging informed radiation dose escalation to sites of recurrent disease and de-escalation to uninvolved areas. |
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Radiation-induced Acute Grade ≥2 Toxicity
大体时间:Baseline to 5-year follow up
|
Acute (less than or equal to 90 days) toxicity will be evaluated by using prospective follow-up and grading according to the latest version of the Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Baseline to 5-year follow up
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Acute and Late GI and GU toxicities
大体时间:Estimated at 6 months and 2 years following treatment
|
Cumulative incidence function will be used to estimate the cumulative incidence of grade ≥2 GI and GU, graded per Common Terminology Criteria for Adverse Events (CTCAE) v6.0. |
Estimated at 6 months and 2 years following treatment
|
|
Local Recurrence
大体时间:Estimated at 2 years and 5 years following treatment
|
Cumulative incidence function with death as a competing risk will be used to estimate local recurrence |
Estimated at 2 years and 5 years following treatment
|
|
Biochemical Disease Free Survival
大体时间:Estimated at 2 years and 5 years following treatment
|
Defined as survival until evidence of either biochemical progression (defined as a rise in prostate-specific antigen (PSA) ≥0.2ng/ml above the PSA nadir followed by a sequentially equal or higher value) following postoperative radiotherapy, clinical or radiological progression, initiation of non-protocol systemic therapy, or death from prostate cancer |
Estimated at 2 years and 5 years following treatment
|
|
Patient-reported quality-of-life assessed by EPIC-26 and IPSS
大体时间:Baseline to 5-year follow-up
|
Patient-Reported Quality of Life will be assessed at baseline and at each follow-up visit (1, 3, 6, 12, 18, 24, 36, 48, and 60 months) using the following assessment questionnaires: EPIC-26 and IPSS |
Baseline to 5-year follow-up
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.